A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- Conditions
- ImmunodeficiencyHematopoietic Stem Cell Transplantation
- Interventions
- Procedure: Allogeneic HSCTRadiation: Total Body Irradiation (TBI)
- Registration Number
- NCT05027945
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
Background:
Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome.
Objective:
To see if stem cell transplants can be successfully performed in people with VEXAS and even improve the disease.
Eligibility:
People ages 18-75 who have VEXAS Syndrome that has caused significant health problems and standard treatment either has not worked or is not available.
Design:
Participants will be screened with:
Physical exam
Medical review
Blood and urine tests
Heart and lung function tests
Bone marrow biopsy
Participants will have a chest x-ray. They will have an imaging scan of the head, chest, abdomen, pelvis, and sinus. They will have a bone density scan. They will have a dental exam and eye exam. They will meet with specialists. They will repeat some screening tests.
Participants will be admitted to the NIH hospital. They have a central venous catheter put into a vein in the chest or neck. They will receive drugs to prepare their bone marrow for the transplant. They may have total body irradiation. They will receive the donor stem cells through the catheter. They will get other drugs to prevent complications and infections. After discharge, they must stay in the DC area for 3 months for weekly study visits.
Participants will have study visits 30, 60, 100, 180, 210, 240, 300, and 360 days later. After that, they will have yearly visits for 2 years and then be contacted yearly by phone....
- Detailed Description
Background:
* In 2019, investigators at the National Institutes of Health defined a new disease syndrome named VEXAS: Vacuoles in bone marrow cells, E1 enzyme mutations, X-linked, Autoinflammatory, Somatic syndrome. This syndrome is characterized by inflammatory and hematologic features and is frequently accompanied by marrow dysplasia, progressive bone marrow failure, and in some cases, the development of overt myelodysplastic syndrome (MDS) or other myeloid neoplasms. Somatic mutations are present at methionine 41 in UBA1, an X-linked gene encoding the major E1 ubiquitin activating enzyme that initiates the majority of cellular ubiquitylation.
* The inflammatory features of VEXAS include fever, pulmonary infiltrates, skin lesions, ear and nose chondritis, musculoskeletal involvement, and elevated inflammatory markers. The hematologic features include cytopenia, characteristic vacuoles in myeloid and erythroid precursors cells, and dysplastic bone marrow. Patients included in the initial description of the syndrome fulfill clinical or classification criteria for both inflammatory diseases (relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, giant cell arteritis) and hematologic conditions (MDS, myeloid neoplasms or plasma cell dyscrasia). The inflammatory features of VEXAS are refractory to treatment other than high doses of glucocorticoids. Increased mortality and frequent morbidity are common in VEXAS secondary to the disease and treatment-related complications. The clinical manifestations of VEXAS are time-dependent. Systemic inflammation typically precedes progressive bone marrow failure with or without the development of hematologic malignancies leading to death. Escalating doses of glucocorticoids are typically administered to control the refractory, progressive features of systemic inflammation. Worsening cytopenias often require transfusion support.
* The discovery of hematologic mosaicism as the genetic driver of rheumatologic/hematologic syndromes defines a novel class of diseases, termed hematoinflammatory diseases (HINDS), and it raises the possibility that therapies aimed at eradicating these clones may be efficacious in this patient population.
Objectives:
Primary Objectives:
* To determine whether allogeneic hematopoietic stem cell transplantation (HSCT) results in sustained donor engraftment at day 100 and one-year post-HSCT.
* To determine whether allogeneic HSCT results in reversal of the clinical phenotype of VEXAS at one year and two years post-HSCT without requiring interval prednisone at \>= 0.5 mg/kg per day for reasons other than graft-versus-host disease (GVHD).
Eligibility:
* Recipients ages 18-75 year-old with or without a somatic mutation in UBA1 who have: 1) the clinical phenotype for VEXAS with refractory cutaneous, pulmonary, musculoskeletal, and/or other recurrent acute inflammatory manifestations, and 2) require \>= 0.5 mg/kg per day of prednisone for inflammatory manifestations OR have cytopenia (transfusion dependent anemia, transfusion dependent thrombocytopenia/platelets \<75,000, neutropenia \<1,000/microL) or myeloid neoplasm (by WHO criteria) or being intolerant or refractory to use steroids.
* Have an 8/8 or 7/8 HLA-matched related or unrelated donor, or a haploidentical related donor.
Design:
-For Recipients with 8/8 HLA Matched Donors:
Participants will receive reduced intensity conditioning with the following regimen:
fludarabine 40 mg/m\^2 IV once daily for four days on days -6, -5, -4, -3 and Busulfan IV for three days on days -6, -5, -and -4 followed by HSCT on day 0. The busulfan dose will be based on pharmacokinetic levels from the test dose and/or real time PKs and will be targeted to AUC of 2500-3500 microMol\*min/L (31-43 mg\*h/L) (2.5 - 2.8 mg/kg IV may be used on D-6 with real time PK for D-5 and D-4).
-For Recipients with 7/8 HLA Matched Donors or Haploidentical Related Donors:
Participants will receive reduced intensity conditioning with the following regimen:
fludarabine 30 mg/m\^2 IV once daily for five days on days -6, -5, -4, -3, and -2, cyclophosphamide 14.5 mg/kg for two days on days -6 and -5, 200 cGy total body irradiation (TBI) on day -1, busulfan IV once daily for two days on days -4 and -3, and HSCT on day 0. The busulfan dose will be based on pharmacokinetic levels from the test dose and/or real time PKs and will be targeted to an AUC of 2500-3500 microMol\*min/L (21-29 mg\*h/L) (2.5 -2.8 mg/kg IV per day may be used on D-4 with real time PK for D-3).
-For Post-Transplant GVHD Prophylaxis:
Post-transplant GVHD prophylaxis in all groups will consist of cyclophosphamide 50 mg/kg IV once daily for 2 days on days +3 and +4, along with mycophenolate mofetil from day +5 to approximately day +45 and tacrolimus from day +5 to approximately day +180.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 54
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B Cyclophosphamide (CY) Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm A Post-Transplant Cyclophosphamide (PTCY) Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm B Allogeneic HSCT Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm B Busulfan test dose Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm B Mycophenolate mofetil (MMF) Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm B Tacrolimus Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm A Allogeneic HSCT Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm A Busulfan test dose Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm A Mycophenolate mofetil (MMF) Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm A Tacrolimus Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm B Busulfan Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm B Total Body Irradiation (TBI) Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm B Post-Transplant Cyclophosphamide (PTCY) Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis Arm A Busulfan Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm A Fludarabine Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis Arm B Fludarabine Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis
- Primary Outcome Measures
Name Time Method Reversal of clinical phenotype of VEXAS +1 and +2 years post HSCT fraction of subjects who achieve complete clinical response without use of additional glucocorticoid therapy and without steroid-sparing therapy
Sustained donor engraftment day +100 and +1 year post HSCT defined as neutrophil recovery with ANC = 500/mm\^3 for 3 consecutive days associated with \> 50% T-cell and myeloid cell donor chimerism at day 100 and one year post-HSCT
- Secondary Outcome Measures
Name Time Method incidence of grade III-IV acute GVHD and moderate to severe chronic GVHD +1 and +2 years post HSCT group comparison of participants with an 8/8 HLA matched related or unrelated donor compared to group of participants with 7/8 HLA matched related or unrelated donor or haploidentical donor. Reported with 95% two-sided confidence intervals. The fractions will also be reported separately by cohort using simple estimates along with 95% two-sided confidence intervals. In addition cumulative incidence curves along with a 95% two-sided confidence interval.
Safety of allo HSCT +1, +2 and +3 years post HSCT Transplant-related toxicity will include if allogeneic HSCT in participants with VEXAS results in the absence of secondary graft failure. The fraction of participants who have secondary graft failure will be reported along with a 95% two-sided confidence interval, separately by cohort.
Overall survival and event free survival +1, +2 and +3 years post HSCT Overall and event free survival will be determined using Using the Kaplan-Meier method, along with the median value and the 95% confidence interval at the median, separately by cohort.
Trial Locations
- Locations (1)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States